Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Gyre Therapeutics (GYRE) over the last 11 years, with Q3 2025 value amounting to $727000.0.

  • Gyre Therapeutics' Other Non Operating Income rose 106933.33% to $727000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$945000.0, marking a year-over-year decrease of 26068.7%. This contributed to the annual value of -$1.7 million for FY2024, which is 928.85% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Other Non Operating Income is $727000.0, which was up 106933.33% from -$145000.0 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Other Non Operating Income registered a high of $858000.0 during Q4 2022, and its lowest value of -$1.6 million during Q4 2024.
  • Moreover, its 5-year median value for Other Non Operating Income was -$17000.0 (2021), whereas its average is -$56105.3.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 439000.0% in 2022, then crashed by 13320000.0% in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Other Non Operating Income stood at -$20000.0 in 2021, then surged by 4390.0% to $858000.0 in 2022, then tumbled by 127.62% to -$237000.0 in 2023, then crashed by 589.45% to -$1.6 million in 2024, then soared by 144.49% to $727000.0 in 2025.
  • Its last three reported values are $727000.0 in Q3 2025, -$145000.0 for Q2 2025, and $107000.0 during Q1 2025.